Proportion of participants who reported an adverse event · women with hirsutism
It is very uncertain whether finasteride 5 mg changes proportion of participants who reported an adverse event compared with flutamide 250 mg once to b.i.d. (very low certainty).
1 finding from 1 review
Participant‐reported improvement of hirsutism 4‐point Likert scale · women with hirsutism
Flutamide 250 mg b.i.d. may leads to higher participant‐reported improvement of hirsutism 4‐point Likert scale compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · patients with heart failure
1 finding from 1 review
Hospitalization/ rehospitalization · patients with heart failure
1 finding from 1 review
Adverse effects · patients with heart failure
1 finding from 1 review
Exercise test (after treatment) · patients with heart failure
1 finding from 1 review
Change in Ejection fraction (%) · patients with heart failure
1 finding from 1 review
Mean change in cardiac output (L/min) · patients with heart failure
1 finding from 1 review
SV(stroke volume) (ml) change · patients with heart failure
1 finding from 1 review
Change in cardiac index (L/min*m²) · patients with heart failure
1 finding from 1 review
Numbers completing double‐blind treatment Number of participants · patients with an acute manic or mixed episode
Aripiprazole showed no clear difference in numbers completing double‐blind treatment Number of participants compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.03 [0.95, 1.12]
2216 participants
Moderate
Requirement for anticholinergics number of participants requiring medication for extrapyramidal side effects · patients with an acute manic or mixed episode
Aripiprazole leads to higher requirement for anticholinergics number of participants requiring… compared with placebo (high certainty).
1 finding from 1 review
RR 3.28 [1.82, 5.91]
730 participants
High
Akathisia Participant report · patients with an acute manic or mixed episode
Aripiprazole leads to higher akathisia Participant report compared with placebo (high certainty).
1 finding from 1 review
RR 3.16 [2.25, 4.43]
2305 participants
High
Nausea · patients with an acute manic or mixed episode
Aripiprazole leads to higher nausea Participant report compared with placebo (high certainty).
1 finding from 1 review
RR 1.5 [1.2, 1.88]
2305 participants
High
Numbers completing the trial (at end of week three) Number of participants · patients with an acute manic or mixed episode
Aripiprazole may leads to higher numbers completing the trial (at end of week three) Number of… compared with other drug treatment (low certainty).
1 finding from 1 review
RR 1.13 [1.03, 1.24]
994 participants
Low
Intervention not reported
Exacerbation rates per participant per year · patients with COPD
The intervention probably leads to lower exacerbation rates per participant per year (moderate certainty).
1 finding from 1 review
Number of participants still in treatment at the end of · patients with treatment of opioid dependence
Any Psychosocial intervention plus pharm showed no clear difference in number of participants still in treatment at the end of compared with pharm standard (high certainty).
1 finding from 1 review
Abstinence · patients with treatment of opioid dependence
Any Psychosocial intervention plus pharm showed no clear difference in number of participants abstinent at the end of compared with pharm standard (high certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes overall survival (absolute effect size estimates based on survival… compared with best supportive care alone (very low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events (at 20 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes proportion of people with ≥ 1 serious adverse events (at 20 months) compared with best supportive care alone (very low certainty).
1 finding from 1 review